tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Michael Ryskin, 11 are a HOLD (26.19%), 21 are a BUY (50%), 10 are a SELL (23.81%).
Analyst Michael Ryskin, currently employed at BAML, carries an average stock price target met ratio of 78.15% that have a potential upside of 25.46% achieved within 156 days.
Michael Ryskin’s has documented 90 price targets and ratings displayed on 14 stocks. The coverage is on Healthcare, Basic Materials sectors.
Most recent stock forecast was given on MRVI, Maravai Lifesciences Holdings at 12-Dec-2023.
Analyst best performing recommendations are on OMIC (SINGULAR GENOMICS SYSTEMS).
The best stock recommendation documented was for OMIC (SINGULAR GENOMICS SYSTEMS) at 6/21/2021. The price target of $780 was fulfilled within 3 days with a profit of $85.2 (12.26%) receiving and performance score of 40.88.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$7
$4.16 (146.48%)
$7
7 days ago
(13-Nov-2024)
3/7 (42.86%)
$3.42 (95.53%)
133
Buy
$6
$3.16 (111.27%)
$8
4 months 9 days ago
(11-Jul-2024)
2/4 (50%)
$1.97 (48.88%)
27
Buy
$14
1 years 6 months 4 days ago
(16-May-2023)
0/3 (0%)
$9.22 (192.89%)
Hold
$10
$7.16 (252.11%)
$28
2 years 5 months 20 days ago
(31-May-2022)
0/2 (0%)
$6.35 (173.97%)
Hold
$10
$8.68 (657.58%)
3 years 10 days ago
(11-Nov-2021)
1/1 (100%)
$-2.96 (-22.84%)
22
What Year was the first public recommendation made by Michael Ryskin?
